2021/08/17 by Filippo Migliorini, Nardeen Kader, Jörg Eschweiler +2
paper · doi:10.1093/bmb/ldab018
crossref created 2021/07/26 · crossref issued 2021/08/17 · crossref published 2021/08/17 · crossref published-online 2021/08/17 · crossref published-print 2021/09/10 · crossref deposited 2021/09/10 · crossref indexed 2026/07/24
Abstract Introduction Greater trochanter pain syndrome (GTPS) is characterized by a persistent and debilitating pain around the greater trochanter. GTPS can be caused by a combination of gluteus medius or minimus tendinopathy, snapping hip or trochanteric bursitis. Source of data Recent published literatures identified from PubMed, EMBASE, Google Scholar, Scopus. Areas of agreement Platelet rich plasma (PRP) and corticosteroids (CCS) injections are useful options to manage symptoms of GTPS. Areas of controversy Whether PRP leads to superior outcomes compared to CCS injections is unclear. Growing points A systematic review and meta-analysis comparing PRP versus CCS in the management of GTPS was conducted. Areas timely for developing research PRP injections are more effective than CCS at approximately 2 years follow-up.